REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Dec 18, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-12-14

Reporting Person: McCorkle Douglas S (VP Controller & Asst Treasurer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-12-17	Common Stock	M	4000.0	$16.8	Acquired	4000.0	Direct
2012-12-17	Common Stock	M	800.0	$16.8	Acquired	4800.0	Direct
2012-12-17	Common Stock	S	800.0	$179.45	Disposed	4000.0	Direct
2012-12-17	Common Stock	M	200.0	$16.8	Acquired	4200.0	Direct
2012-12-17	Common Stock	S	200.0	$178.19	Disposed	4000.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-12-17	Incentive Stock Option (right to buy)	$16.8	M	4000.0	Disposed	2018-12-17	Common Stock (4000.0)	Direct
2012-12-17	Incentive Stock Option (right to buy)	$16.8	M	800.0	Disposed	2018-12-17	Common Stock (800.0)	Direct
2012-12-17	Incentive Stock Option (right to buy)	$16.8	M	200.0	Disposed	2018-12-17	Common Stock (200.0)	Direct
2012-12-14	Non-Qualified Stock Option (right to buy)	$179.13	A	26000.0	Acquired	2022-12-14	Common Stock (26000.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4008.0	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 800 shares of Company stock on December 17, 2012 at prices ranging from $179.02 to $179.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 200 shares of Company stock on December 17, 2012 at prices ranging from $178.06 to $178.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2012 at each separate price.

F4: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

F5: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

F6: The stock option award vests in four equal annual installments, commencing one year after the date of grant.